AML BitCoin Enters Phase II of ICO
NAC Foundation, LLC announces today that the initial coin offering for the AML BitCoin – the world’s only patent-pending compliant digital currency – has been extended for another month to accommodate a torrent of last minute, new coin purchasers and the demands of thousands of current owners of the coin, who have had difficulty navigating the process of establishing the specialized wallet required to hold the innovative digital currency.
This second phase of the AML BitCoin initial coin offering will see an increase in the price of the coin, from US $1.00 to US $1.25. The company has already been contacted by prospective purchasers in the slightly higher priced Phase II, and anticipates a further price increase to US $1.50 within a week or two.
HitBTC, one of the world’s largest and most active digital currency exchanges, was prepared to list the AML BitCoin for trading on December 15, 2017, with anticipation that the frenetic worldwide activity and excitement greeting the new cryptocurrency would cement the coin as one of the world’s dominant digital currencies.
Instead, the coin will be listed mid-January 2018, giving time to NAC Foundation to process the flood of orders pouring into the company, and assist these new coin owners with the unique AML BitCoin wallet process.
NAC Foundation has not been consumed only with the massive response to the launch of AML BitCoin, but also with negotiations around the world to enable the coin, and its underlying patent-pending anti-money laundering and know your customer features, to be integrated into governmental and industry payment systems. NAC Foundation CEO, Marcus Andrade, anticipates a public announcement within the next month announcing a partnership with one of the largest Latin American companies in the financial sector.
Additionally, Andrade returns to Europe in a few weeks to conclude a series of partnerships with key governmental and industry stakeholders, that should rapidly advance AML BitCoin’s goal of becoming the one digital currency that merchants, banks and other commercial enterprises can safely utilize.
To participate in the AML BitCoin Token Sale, please visit www.amltoken.com .
About NAC Foundation
NAC Foundation, headquartered in the U.S., is the creator of the AML BitCoin, the world's only patent-pending digital currency with anti-money laundering, know-your-customer, anti-terrorism and theft-resistant properties. AML BitCoin is compliant with all major national security and financial protection laws and regulations, including the USA PATRIOT Act and the Bank Secrecy Act. NAC's mission is to strengthen the acceptance and use of digital currencies by advancing throughout the world security compliance, combined with blockchain technology. For more information, please visit www.amlbitcoin.com or www.amltoken.com .
AML BitCoin is the source of this content. Virtual currency is not legal tender, is not backed by the government, and accounts and value balances are not subject to consumer protections. This press release is for informational purposes only. The information does not constitute investment advice or an offer to invest.
NAC Foundation - AML BitCoin
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ERYTECH-PHARMA24.4.2018 22:32 | pressemeddelelse
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
NV-RIMINI-STREET24.4.2018 18:02 | pressemeddelelse
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation
NOVALIQ-GMBH24.4.2018 17:55 | pressemeddelelse
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI
PA-PPG24.4.2018 15:09 | pressemeddelelse
PPG Reports Sustainability Progress, New 2025 Goals
BIOIBERICA24.4.2018 14:19 | pressemeddelelse
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries
TX-ASURAGEN24.4.2018 14:03 | pressemeddelelse
Asuragen to Present at World CB & CDx Europe Summit in London, UK
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum